Therapy News and Research

RSS

Monteris secures financing to commercialize NeuroBlate System

Monteris Medical Inc., a privately held medical device company dedicated to the development of innovative MRI guided, laser-based cancer treatments announced today it has secured $9 million in financing to support the continued commercialization of the company's NeuroBlate System (formerly AutoLITT) within the North American neurosurgery market.

7 May 2012

Positive long-term outcome data for chronic ITP patients treated with rituxamab

A new analysis concludes that rituximab, a drug commonly used to treat blood cancers, leads to treatment responses lasting at least five years in approximately one quarter of patients with low platelet counts and a risk of bleeding due to chronic immune thrombocytopenic purpura (ITP).

7 May 2012

Vertex reports interim data from VX-809 and KALYDECO combination Phase 2 study for cystic fibrosis

Vertex Pharmaceuticals Incorporated announced today an interim analysis of data from an ongoing Phase 2 study of VX-809 and KALYDECO (ivacaftor) that showed significant improvements in lung function (FEV1) among adults with cystic fibrosis (CF) who have two copies.

7 May 2012

CardioKinetix Parachute Ventricular Partitioning Device trial data presented at 2012 EuroPCR

CardioKinetix Inc., a medical device company pioneering a catheter-based treatment for heart failure, today announced that clinical trial data from the first-of-its-kind Parachute Ventricular Partitioning Device for the treatment of patients with ischemic heart failure will be presented at the 2012 EuroPCR Conference in Paris.

7 May 2012

Positive results from PROLOR Biotech's hGH-CTP Phase II trial for growth hormone deficiency

PROLOR Biotech, Inc. today reported top-line results from a Phase II four-month treatment extension study of hGH-CTP, its long-acting version of human growth hormone, in growth hormone deficient adults.

7 May 2012

Positive results from Dainippon Sumitomo Pharma's LATUDA trials for bipolar I depression

Dainippon Sumitomo Pharma Co., Ltd. announced today results from two Phase 3 clinical trials designed to evaluate the efficacy and safety of LATUDA as adjunctive therapy and monotherapy, respectively, in patients with bipolar I depression (PREVAIL 1 and PREVAIL 2; PRogram to EValuate the Antidepressant Impact of Lurasidone).

7 May 2012

Active video games may benefit kids with cerebral palsy

Like their healthy peers, children with disabilities may spend too much time in front of a video screen. For children with cerebral palsy (CP), this leads to an even greater risk of being overweight or developing health issues such as diabetes or musculoskeletal disorders.

7 May 2012

Automated way to record electrical activity inside neurons in the living brain

Gaining access to the inner workings of a neuron in the living brain offers a wealth of useful information: its patterns of electrical activity, its shape, even a profile of which genes are turned on at a given moment. However, achieving this entry is such a painstaking task that it is considered an art form; it is so difficult to learn that only a small number of labs in the world practice it.

7 May 2012

Researchers make white fat take on characteristics of brown fat

Brown seems to be the color of choice when it comes to the types of fat cells in our bodies. Brown fat expends energy, while its counterpart, white fat stores it. The danger in white fat cells, along with the increased risk for diabetes and heart disease it poses, seems especially linked to visceral fat. Visceral fat is the build-up of fat around the organs in the belly.

7 May 2012

Oral nutriceutical restores vision to otherwise hopeless patients facing permanent loss

There may be new found hope for patients whose vision is threatened when medicine injected directly into the eyes fails to cause abnormal blood vessels to recede. While injectable drugs called angiogenesis (an-gee-oh-jen-esis) inhibitors are considered a modern miracle and have become the standard of care for patients with the fast-progressive form of macular degeneration, they are not foolproof.

7 May 2012

Researchers separate low and high-PSA prostate cancer cells

Prostate cancer cells that defy treatment and display heightened tumor-generating capacity can be identified by levels of prostate specific antigen (PSA) expressed in the tumor cells, a research team led by scientists at The University of Texas MD Anderson Cancer Center reports in the May 3 edition of Cell Stem Cell.

7 May 2012

Accentia, Johns Hopkins co-host meeting with prospective clinical trial investigators at AAN meeting

Accentia Biopharmaceuticals, Inc. today announced that the Company and leading physicians from Johns Hopkins University co-hosted a meeting with prospective clinical trial investigators at the recent American Academy of Neurology (AAN) Annual Meeting in New Orleans.

7 May 2012

Radiofrequency ablation during breast cancer surgery can provide effective alternative to XRT

Radiofrequency ablation of the lumpectomy site during breast cancer surgery can provide an effective alternative to post-operative external radiation therapy (XRT) and reduce repeat surgeries to achieve clear tumor margins, according to one of the first published long-term studies to examine this new treatment protocol.

5 May 2012

iCAD, Breastlink announce agreement to offer Xoft brachytherapy system

iCAD, Inc., an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, and Breastlink Medical Group in Southern California, today announced an agreement that will make the Xoft Axxent Electronic Brachytherapy System available to breast cancer patients treated at Breastlink.

5 May 2012

Sound Interventions completes ultrasound clinical trial on resistant hypertension

Sound Interventions, Inc. today announced the successful completion of the company's First-In-Human clinical trial (SOUND-ITV) to treat resistant hypertension.

5 May 2012

MicroRNAs in breast cancer play a role in development of resistance to tamoxifen

Many breast cancer patients are treated with a drug called tamoxifen. The substance blocks the effect of estrogen and thus suppresses the growth signals of this hormone in cancer cells. When resistance to the drug develops, tumor cells change their growth program: They change their behavior and shape, become more mobile and also adopt the ability to invade surrounding tissue. Scientists working with PD (Associate Professor) Dr. Stefan Wiemann of the German Cancer Research Center (DKFZ) have now also observed these changes in tamoxifen resistant breast cancer cells.

5 May 2012

Flavan-3-ols, SoyLife can improve biomarkers of CVD risk in postmenopausal type 2 diabetic patients

A new, one-year, double-blind controlled clinical study shows that cacao-flavonoids and soy isoflavones can significantly improve biomarkers of CVD risk in postmenopausal women with type 2 diabetes.

5 May 2012

DTT releases ditto dental electronic device

Diversionary Therapy Technologies (DTT) is pleased to announce the release of ditto dental, an interactive electronic device containing augmented reality content to prepare children for dental procedures, resulting in reduced stress and anxiety for the pediatric patient and increased clinical productivity.

5 May 2012

Research roundup: Chronic disease interventions could save states money; Drilling into childhood cancer disparities; National heart emergency care system proposed

Urban Institute: Potential Savings Through Prevention Of Avoidable Chronic Illness Among CalPERS State Active Members -- California is one of many states in financial crisis, and according to this report, it could save millions of dollars on state employee health benefits by preventing chronic disease.

5 May 2012

New light on many biological differences between individual breast cancers

New findings presented at Europe's leading breast cancer translational research conference this year shed new light on the many biological differences between individual breast cancers.

4 May 2012

Therapy News and Research

Monteris secures financing to commercialize NeuroBlate System

Positive long-term outcome data for chronic ITP patients treated with rituxamab

Vertex reports interim data from VX-809 and KALYDECO combination Phase 2 study for cystic fibrosis

CardioKinetix Parachute Ventricular Partitioning Device trial data presented at 2012 EuroPCR

Positive results from PROLOR Biotech's hGH-CTP Phase II trial for growth hormone deficiency

Positive results from Dainippon Sumitomo Pharma's LATUDA trials for bipolar I depression

Active video games may benefit kids with cerebral palsy

Automated way to record electrical activity inside neurons in the living brain

Researchers make white fat take on characteristics of brown fat

Oral nutriceutical restores vision to otherwise hopeless patients facing permanent loss

Researchers separate low and high-PSA prostate cancer cells

Accentia, Johns Hopkins co-host meeting with prospective clinical trial investigators at AAN meeting

Radiofrequency ablation during breast cancer surgery can provide effective alternative to XRT

iCAD, Breastlink announce agreement to offer Xoft brachytherapy system

Sound Interventions completes ultrasound clinical trial on resistant hypertension

MicroRNAs in breast cancer play a role in development of resistance to tamoxifen

Flavan-3-ols, SoyLife can improve biomarkers of CVD risk in postmenopausal type 2 diabetic patients

DTT releases ditto dental electronic device

Research roundup: Chronic disease interventions could save states money; Drilling into childhood cancer disparities; National heart emergency care system proposed

New light on many biological differences between individual breast cancers

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News